Saturday 17 October 2026
Export LIANY’s income statement to Excel — free account
LianBio Sponsored ADR
LIANY Healthcare Biotechnology
0.05
0.00
0.00%
Follow LIANY
| Older periods | Mar '23 | Jun '23 | Sep '23 | Dec '23 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(33.36%) | (29.51%) | (32.42%) | 70.96% | |
| (29.78%) | (26.39%) | (28.62%) | 66.19% | ||
ROIC |
0.00% | 0.00% | 0.00% | (450.47%) | |
Return on Tangible Assets |
(39.06%) | (33.79%) | (37.51%) | 53.56% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.98) | (0.79) | (0.78) | 2.40 | |
Free Cash Flow |
(105.24) | (84.87) | (83.99) | 258.79 | |
Capital Expenditures |
(1.52) | (1.24) | (0.46) | (0.37) | |
| Other line items | |||||
Cash ROIC |
(18.76%) | (16.23%) | (17.20%) | 22.53% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.17 | 0.79 | 0.30 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
1,743.92 | 564.13 | 1,838.43 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(19.13) | (12.19) | (10.75) | — | |
Operating CF/Net income |
0.97 | 0.97 | 0.95 | 0.83 | |
Depreciation/Fixed assets |
0.37 | 0.49 | 0.55 | 0.63 | |
Capex/Depreciation |
(1.44) | (0.99) | (0.36) | (0.28) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.97) | (0.78) | (0.78) | 2.40 | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates